Joel P. Wagner

1.0k total citations
14 papers, 477 citations indexed

About

Joel P. Wagner is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Joel P. Wagner has authored 14 papers receiving a total of 477 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Molecular Biology, 6 papers in Oncology and 2 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Joel P. Wagner's work include CAR-T cell therapy research (3 papers), Computational Drug Discovery Methods (2 papers) and Immune cells in cancer (2 papers). Joel P. Wagner is often cited by papers focused on CAR-T cell therapy research (3 papers), Computational Drug Discovery Methods (2 papers) and Immune cells in cancer (2 papers). Joel P. Wagner collaborates with scholars based in United States, Switzerland and Taiwan. Joel P. Wagner's co-authors include Douglas A. Lauffenburger, Mark F. Ciaccio, Chih‐Pin Chuu, Richard B. Jones, Fang Li, Sean P. Palecek, Amy J. Karlsson, Philip Oshel, David R. Andes and Karen Marchillo and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Blood and Neurology.

In The Last Decade

Joel P. Wagner

12 papers receiving 469 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Joel P. Wagner United States	9	294	104	101	69	61	14	477
Kristina Oresic Bender United States	7	240 0.8×	81 0.8×	73 0.7×	38 0.6×	71 1.2×	8	451
Tomáš Raček Germany	16	422 1.4×	42 0.4×	98 1.0×	98 1.4×	48 0.8×	35	685
Elisabeth M. Storck United Kingdom	10	301 1.0×	43 0.4×	48 0.5×	66 1.0×	31 0.5×	12	466
Jonathan St‐Germain Canada	18	609 2.1×	53 0.5×	89 0.9×	65 0.9×	56 0.9×	33	841
Amir Banaei‐Esfahani Switzerland	13	410 1.4×	70 0.7×	59 0.6×	59 0.9×	19 0.3×	20	569
Mehdi Bouhaddou United States	13	313 1.1×	189 1.8×	65 0.6×	54 0.8×	61 1.0×	24	583
Anjali Seth United States	13	246 0.8×	88 0.8×	63 0.6×	82 1.2×	32 0.5×	23	425
Kari Salokas Finland	11	413 1.4×	61 0.6×	64 0.6×	24 0.3×	34 0.6×	26	618
Nikita V. Ivanisenko Russia	18	484 1.6×	57 0.5×	101 1.0×	63 0.9×	55 0.9×	61	715
Christopher Chidley United States	8	363 1.2×	79 0.8×	64 0.6×	36 0.5×	40 0.7×	10	538

Countries citing papers authored by Joel P. Wagner

Since Specialization

Citations

This map shows the geographic impact of Joel P. Wagner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joel P. Wagner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joel P. Wagner more than expected).

Fields of papers citing papers by Joel P. Wagner

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Joel P. Wagner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joel P. Wagner. The network helps show where Joel P. Wagner may publish in the future.

Co-authorship network of co-authors of Joel P. Wagner

This figure shows the co-authorship network connecting the top 25 collaborators of Joel P. Wagner. A scholar is included among the top collaborators of Joel P. Wagner based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Joel P. Wagner. Joel P. Wagner is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

Lee, Lang Ho, Fanying Tang, Lauren Fairchild, et al.. (2025). Defining Non–small Cell Lung Cancer Tumor Microenvironment Changes at Primary and Acquired Immune Checkpoint Inhibitor Resistance Using Clinical and Real-World Data. Cancer Research Communications. 5(6). 1049–1059.

Shi, Xinyi, et al.. (2025). Abstract C035: Arrayed CRISPR Screening Reveals EFNA1 as a Non-Cell-Autonomous Essential Gene in Pancreatic Cancer Cells. Molecular Cancer Therapeutics. 24(10_Supplement). C035–C035.

Huuhtanen, Jani, Oscar Brück, Karita Peltonen, et al.. (2021). Single-Cell Characterization of the Immune and Leukemic Cells Following Anti-TIM3 and Hypomethylating Agent Combination Therapy in Patients with AML or MDS. Blood. 138(Supplement 1). 801–801. 1 indexed citations

Schöffski, Patrick, Nicole Concin, Cristina Suárez, et al.. (2021). A Phase 1 Study of a CDH6-Targeting Antibody-Drug Conjugate in Patients with Advanced Solid Tumors with Evaluation of Inflammatory and Neurological Adverse Events. Oncology Research and Treatment. 44(10). 547–556. 19 indexed citations

Liu, Siqi, Brian Granda, Rajiv Chopra, et al.. (2020). A CRISPR Screen Reveals Resistance Mechanisms to CD3-Bispecific Antibody Therapy. Cancer Immunology Research. 9(1). 34–49. 14 indexed citations

Menghi, Francesca, Koichiro Inaki, Pooja Kumar, et al.. (2016). The tandem duplicator phenotype as a distinct genomic configuration in cancer. Proceedings of the National Academy of Sciences. 113(17). E2373–82. 65 indexed citations

Inaki, Koichiro, Francesca Menghi, Xing Yi Woo, et al.. (2014). Systems consequences of amplicon formation in human breast cancer. Genome Research. 24(10). 1559–1571. 21 indexed citations

Wagner, Joel P., Alejandro Wolf‐Yadlin, Mark Sevecka, et al.. (2013). Receptor Tyrosine Kinases Fall into Distinct Classes Based on Their Inferred Signaling Networks. Science Signaling. 6(284). ra58–ra58. 3 indexed citations

Forman, Mervyn B., Jeng‐Sen Tseng, John Palcza, et al.. (2012). The Novel BACE Inhibitor MK-8931 Dramatically Lowers CSF A Peptides in Healthy Subjects: Results from a Rising Single Dose Study (PL02.004). Neurology. 78(Meeting Abstracts 1). PL02.004–PL02.004. 13 indexed citations

10.

Kim, Hyung‐Do, Aaron S. Meyer, Joel P. Wagner, et al.. (2011). Signaling Network State Predicts Twist-Mediated Effects on Breast Cell Migration Across Diverse Growth Factor Contexts. Molecular & Cellular Proteomics. 10(11). M111.008433–M111.008433. 25 indexed citations

11.

Ciaccio, Mark F., Joel P. Wagner, Chih‐Pin Chuu, Douglas A. Lauffenburger, & Richard B. Jones. (2010). Systems analysis of EGF receptor signaling dynamics with microwestern arrays. Nature Methods. 7(2). 148–155. 160 indexed citations

12.

Naegle, Kristen M., Melissa Gymrek, Brian A. Joughin, et al.. (2010). PTMScout, a Web Resource for Analysis of High Throughput Post-translational Proteomics Studies. Molecular & Cellular Proteomics. 9(11). 2558–2570. 37 indexed citations

13.

Brainard, Diana M., David H. Wright, Peng Sun, et al.. (2009). 937 SAFETY, TOLERABILITY, AND PHARMACOKINETICS AFTER SINGLE AND MULTIPLE DOSES OF MK-3281 IN HEALTHY SUBJECTS. Journal of Hepatology. 50. S341–S341. 7 indexed citations

14.

Li, Fang, Amy J. Karlsson, Joel P. Wagner, et al.. (2007). Eap1p, an Adhesin That Mediates Candida albicans Biofilm Formation In Vitro and In Vivo. Eukaryotic Cell. 6(6). 931–939. 112 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact